ExpreS2ion announces upcoming presentation of Phase I/IIa malaria vaccine trial results by Jenner Institute
Horsholm, Denmark, October 18, 2016 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its collaboration partner, Jenner Institute of the University of Oxford, will present the results from the Phase I/IIa clinical studies of its RH5.1 blood stage malaria vaccine at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting on the 31st of October in New Orleans.The study assesses the safety, immunogenicity, and efficacy of the blood-stage Plasmodium falciparum malaria antigen RH5.1, which is produced with ExpreS2ion’s technology platform ExpreS2. “We